Publication date: May 03, 2019
No significant difference was seen after 36 months in average Unified Parkinson Disease Rating Scale (UPDRS) Part I-III scores measured in the ON state for patients receiving isradipine (DynaCirc) at 10 mg daily versus placebo (treatment effect 0. 27 points, 95% CL -2. 5 to 3. 0, P=0. 85), reported Tanya Simuni, MD, of the Northwestern University Feinberg School of Medicine, and colleagues.
“The study was based on solid mechanistic rationale, partly on animal data, and epidemiological data supporting that this mechanism is relevant to this human disease,” Simuni told MedPage Today.
In 2007, findings from a study published in Nature led by James Surmeier, PhD, at Northwestern, linked the death of dopaminergic neurons — the hypothesized the cause of Parkinson’s disease — with the excitement of calcium channels in these cells.
The initial studies were followed by a 2013 phase II trial conducted by the Parkinson’s Study group, STEADY-PD, which established 10 mg of controlled-release isradipine as the maximum tolerable dosage for patients with early Parkinson’s disease; with fewer than 30 patients in each study arm, it was not powered to demonstrate efficacy.
“What this study demonstrates is that this particular drug at this particular dose does not have the benefit of slowing progression of early Parkinson’s disease,” she said.
- Felodipine induces autophagy in mouse brains with pharmacokinetics amenable to repurposing.
- Common blood pressure medication may be repurposed to treat dementia and Parkinson’s
- Can a blood pressure drug protect the brain from Parkinson’s?
- Michael J. Fox Foundation and 23andMe Launch Fox DEN, a Data Platform Combining Patient-Reported Outcomes and Genetic Information in Parkinson’s
- Basal and Evoked Neurotransmitter Levels in Parkin, DJ-1, PINK1 and LRRK2 Knockout Rat Striatum.
- Leukemia Drug Provides Benefits in PD, Researchers Find
- FDA to Review Istradefylline NDA for Parkinson Disease Again
- Impulse Control Disorders in Parkinson’s Disease.